Grifols GRF.MC
Grifols is a Spanish pharmaceutical company dedicated to the research, development, and production of plasma-derived medicines, with an integrated business model that includes a network of donation centers and the commercialization of hemoderivatives and diagnostics. Grifols presents a very attractive valuation (forward P/E of 8.49 and PEG of 0.24) and earnings growth of 32.9%, but its high leverage (Net Debt/EBITDA of 5.36) and declining revenues (-0.9%) weigh on its risk and quality profile.
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Grifols is a Spanish pharmaceutical company dedicated to the research, development, and production of plasma-derived medicines, with an integrated business model that includes a network of donation centers and the commercialization of hemoderivatives and diagnostics. Grifols presents a very attractive valuation (forward P/E of 8.49 and PEG of 0.24) and earnings growth of 32.9%, but its high leverage (Net Debt/EBITDA of 5.36) and declining revenues (-0.9%) weigh on its risk and quality profile.
Score by category
| Category | Score |
|---|---|
| Financial health | 4.4 |
| Quality / Moat | 4.4 |
| Valuation | 8.0 |
| Growth | 6.2 |
| Dividend | 5.4 |
| Momentum | 1.0 |
| Risk & Context | 3.0 |
OVERALL SCORE: 5.0/10
Context and risks
Grifols operates in Spain, a country with elevated governance risk. Additionally, its high leverage (Net Debt/EBITDA of 5.36) and exposure to a rising rate environment in Europe (ECB hiking) increase financial and refinancing risk.
News considered in the analysis
- Grifols (BME:GRF) Stock May Be Below Fair Value On Earnings — Análisis de valoración que sugiere que la acción está infravalorada; refuerza la lectura de valoración barata pero no aporta información nueva material.
- European Equities Traded in the US as American Depositary Receipts Edge Higher in Friday Trading; Down for Week — Movimiento genérico de ADRs sin información específica sobre la compañía.
- GRFS vs. SDZNY: Which Stock Should Value Investors Buy Now? — Comparativa de valoración entre dos valores sin datos concretos nuevos.
- European Equities Traded in the US as American Depositary Receipts Drop in Thursday Trading — Movimiento de mercado genérico, sin relevancia para los fundamentales de Grifols.
- GRFS or SDZNY: Which Is the Better Value Stock Right Now? — Artículo de comparación de valor sin información nueva.
Verdict: Hold; the cheap valuation and earnings growth are attractive, but high leverage and governance risk in Spain warrant caution.
Main risk: High leverage (Net Debt/EBITDA of 5.36) in a rising European interest rate environment, which makes refinancing more expensive and pressures financial health.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →